Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan and Cisplatin in Advanced Solid Malignancies
NCT07782346Phase 1Not yet recruiting
- Sponsor
- National Health Research Institutes
- Start
- Dec 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nanoliposomal irinotecan in solid tumor, sponsored by National Health Research Institutes. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Dose at 28 days. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07782346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782346.